BRPI0415833A - derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos - Google Patents

derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos

Info

Publication number
BRPI0415833A
BRPI0415833A BRPI0415833-4A BRPI0415833A BRPI0415833A BR PI0415833 A BRPI0415833 A BR PI0415833A BR PI0415833 A BRPI0415833 A BR PI0415833A BR PI0415833 A BRPI0415833 A BR PI0415833A
Authority
BR
Brazil
Prior art keywords
lower alkyl
hydrogen
treatment
trifluoromethyl
halogen
Prior art date
Application number
BRPI0415833-4A
Other languages
English (en)
Inventor
Simona Maria Ceccarelli
Emmanuel Pinard
Henri Stalder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0415833A publication Critical patent/BRPI0415833A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE TRIAZA-ESPIROPIPERIDINA PARA USO COMO INIBIDORES DE GLYT-1 NO TRATAMENTO DE DISTúRBIOS NEUROLóGICOS E NEUROPSIQUIáTRICOS". A invenção refere-se aos compostos da fórmula geral em que A-Aé -CH~ 2~-CH~ 2~-, -CH~ 2~-CH~ 2~-CH~ 2~-, -CH~ 2~-O- ou -0-CH~ 2~-; X é hidrogênio ou hidróxi; R¬ 1¬ é arila ou heteroarila, substituída ou não substituída por um ou mais substituintes, selecionados dentre o grupo consistindo de alquila inferior, alcóxi inferior, halogênio ou trifluorometila; R¬ 2¬ é arila ou heteroarila, substituída ou não substituída por um ou mais substituintes, selecionados dentre o grupo consistindo de alquila inferior, alcóxi inferior, halogênio ou trifluorometila, ou é alquila inferior, -(CH~ 2~)~ n~-Cicloalquila, -(CH~ 2~)~ n~-CF~ 3~, -(CH~ 2~)~ p~O-alquila inferior, -(CH~ 2~)~ 1,2~-fenila, opcionalmente substituída por halogênio, alquila inferior, alcóxi inferior ou trifluorometila, ou é -(CH~ 2~)~ p~-NR<39>R<39><39>, em que R<39> e R<39><39> formam juntos com o N-átomo um anel heterocíclico, selecionado dentre o grupo consistindo de piperidina, morfolina, tiomorfolina ou 1,1-dioxo-tiomorfolina; R¬ 3¬, R¬ 4¬ são independentemente um de cada outro hidrogênio, alquila inferior, fenila ou benzila; R¬ 5¬ é hidrogênio, alquila inferior ou benzila; R¬ 6¬ é hidrogênio ou alquila inferior; n é 0,1 ou 2; e p é 2 ou 3; e aos sais de adição de ácido farmaceuticamente aceitáveis dos mesmos para o tratamento de psicoses, dor, disfunção neurodegenerativa em memória e aprendizagem, esquizofrenia, demência e outras doenças em que os processos cognitivos são prejudicados como distúrbios do déficit de atenção ou mal de Alzheimer.
BRPI0415833-4A 2003-10-23 2004-10-14 derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos BRPI0415833A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03024415 2003-10-23
PCT/EP2004/011552 WO2005040166A1 (en) 2003-10-23 2004-10-14 Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
BRPI0415833A true BRPI0415833A (pt) 2007-01-02

Family

ID=34486099

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415833-4A BRPI0415833A (pt) 2003-10-23 2004-10-14 derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos

Country Status (19)

Country Link
US (1) US7189850B2 (pt)
EP (1) EP1678177B1 (pt)
JP (1) JP4490434B2 (pt)
KR (1) KR100798161B1 (pt)
CN (1) CN100467468C (pt)
AR (1) AR046186A1 (pt)
AU (1) AU2004283843B2 (pt)
BR (1) BRPI0415833A (pt)
CA (1) CA2543308C (pt)
CO (1) CO5690643A2 (pt)
DE (1) DE602004010419T2 (pt)
ES (1) ES2297502T3 (pt)
IL (1) IL174734A (pt)
MX (1) MXPA06004305A (pt)
NO (1) NO20061419L (pt)
RU (1) RU2006117368A (pt)
TW (1) TW200526662A (pt)
WO (1) WO2005040166A1 (pt)
ZA (1) ZA200603221B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110724A2 (en) 2005-04-11 2006-10-19 Yale University Method of treating schizophrenia prodrome
DE102005038141A1 (de) * 2005-08-12 2007-02-15 Grünenthal GmbH Substituierte 8-(3-Aminopropyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-on-Derivate
BRPI0708607A2 (pt) 2006-03-08 2011-06-07 Hoffmann La Roche 1,5-diidro-imidazol-2-onas 4-amino-1,5-substituìdas
JP2009530247A (ja) * 2006-03-16 2009-08-27 グラクソ グループ リミテッド Ｎ−フェニル−２−オキソ−１，４−ジアザスピロ［４．５］デカ−３−エン−１−イルアセトアミド誘導体およびグリシン輸送体阻害剤としてのそれらの使用
GB0607398D0 (en) * 2006-04-12 2006-05-24 Glaxo Group Ltd Compounds
EP2035420A2 (en) * 2006-06-20 2009-03-18 Wyeth a Corporation of the State of Delaware Kv1.5 potassium channel inhibitors
EP2121690A1 (en) * 2007-02-01 2009-11-25 Glaxo Group Limited Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
EP2108018A2 (en) * 2007-02-01 2009-10-14 Glaxo Group Limited 8-oxa-1,4-diazaspiro [4,5] dec-3-en-1-yl and 1,4,8-triazaspiro [4,5] dec-3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders
GB0701955D0 (en) * 2007-02-01 2007-03-14 Glaxo Group Ltd Compounds
EP2121623A1 (en) * 2007-02-01 2009-11-25 Glaxo Group Limited Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
JP2010517959A (ja) * 2007-02-01 2010-05-27 グラクソ グループ リミテッド ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
JP2010517964A (ja) * 2007-02-01 2010-05-27 グラクソ グループ リミテッド ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
GB0701985D0 (en) * 2007-02-01 2007-03-14 Glaxo Group Ltd Compounds
CA2688493C (en) 2007-05-31 2016-04-19 Sepracor Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
WO2009003867A1 (en) 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
US8420670B2 (en) 2007-08-22 2013-04-16 Abbott Laboratories 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
WO2009034062A1 (en) * 2007-09-11 2009-03-19 Glaxo Group Limited Compounds which inhibit the glycine transporter and uses thereof in medicine
US9413889B2 (en) * 2007-09-18 2016-08-09 Telecommunication Systems, Inc. House number normalization for master street address guide (MSAG) address matching
US7981904B2 (en) * 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
MX2010010773A (es) 2008-04-01 2011-04-11 Abbott Gmbh & Co Kg Tetrahidroisoquinolinas, composiciones farmaceuticas que las contienen y su uso en terapia.
ES2445143T3 (es) * 2009-01-27 2014-02-28 F. Hoffmann-La Roche Ag Piperidinas sustituidas por aroilamino y heteroaroilamino como inhibidores de GLYT-1
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
MX379532B (es) 2010-10-25 2025-03-10 G1 Therapeutics Inc Inhibidores de cdk.
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2014006004A (es) 2011-11-18 2015-04-16 Abbvie Deutschland Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia.
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013148748A1 (en) 2012-03-29 2013-10-03 Francis Xavier Tavares Lactam kinase inhibitors
JP2015157764A (ja) * 2012-06-14 2015-09-03 大正製薬株式会社 グリシントランスポーター阻害物質
US9527857B2 (en) 2013-03-15 2016-12-27 GI Therapeutics, Inc. HSPC-sparing treatments for RB-positive abnormal cellular proliferation
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US20140271460A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly Active Anti-Neoplastic and Anti-Proliferative Agents
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2016004934A (es) 2013-10-17 2016-12-20 Abbvie Deutschland Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
EP3057960B1 (en) 2013-10-17 2019-02-27 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
JP6626454B2 (ja) 2014-01-06 2019-12-25 アルゴメディクス インコーポレイテッド Ｔｒｐａ１モジュレーター
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
EP3134406A1 (en) 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
EP3215500A1 (en) 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituted azetidinyl compounds as glyt1 inhibitors
JP6814814B2 (ja) 2016-03-17 2021-01-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｔａａｒのアゴニストとしての活性を有する５−エチル−４−メチル−ピラゾール−３−カルボキサミド誘導体
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
TWI823845B (zh) 2017-01-06 2023-12-01 美商G1治療公司 用於治療癌症的組合療法
EP4455146A3 (en) 2017-06-29 2025-01-01 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
CN120817904A (zh) 2018-08-24 2025-10-21 法码科思莫斯有限公司 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0921125B1 (en) * 1997-12-05 2002-01-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro[4,5]decan-4-on derivatives
ATE212635T1 (de) * 1997-12-05 2002-02-15 1,3,8-triazaspiro(4,5)decan-4-on-derivate
BRPI0407543A (pt) * 2003-02-17 2006-02-14 Hoffmann La Roche derivados de piperidina-benzenossulfonamida

Also Published As

Publication number Publication date
DE602004010419D1 (de) 2008-01-10
ZA200603221B (en) 2009-04-29
CN1871238A (zh) 2006-11-29
CO5690643A2 (es) 2006-10-31
IL174734A (en) 2010-05-31
JP4490434B2 (ja) 2010-06-23
DE602004010419T2 (de) 2008-10-09
WO2005040166A1 (en) 2005-05-06
CA2543308A1 (en) 2005-05-06
AU2004283843A1 (en) 2005-05-06
EP1678177A1 (en) 2006-07-12
AR046186A1 (es) 2005-11-30
CA2543308C (en) 2012-03-06
IL174734A0 (en) 2006-08-20
ES2297502T3 (es) 2008-05-01
CN100467468C (zh) 2009-03-11
KR20060076317A (ko) 2006-07-04
AU2004283843B2 (en) 2010-04-22
TW200526662A (en) 2005-08-16
MXPA06004305A (es) 2006-06-05
EP1678177B1 (en) 2007-11-28
US20050107373A1 (en) 2005-05-19
US7189850B2 (en) 2007-03-13
KR100798161B1 (ko) 2008-01-28
NO20061419L (no) 2006-07-14
RU2006117368A (ru) 2007-12-10
JP2007509097A (ja) 2007-04-12

Similar Documents

Publication Publication Date Title
BRPI0415833A (pt) derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos
BRPI0407543A (pt) derivados de piperidina-benzenossulfonamida
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacêutico
EA200501516A1 (ru) Производные 2,3,6-тризамещённого-4-пиримидона
BRPI0112475B8 (pt) n-óxido de derivados 4-fenil-piridina como antagonista de receptor nk1, seu medicamento, seu processo de preparação e seus usos
BRPI0413536B8 (pt) derivados de 1-benzoil-piperazina, seu uso e medicamento que os compreende
NO20073667L (no) [4-(heteroaryl) piperazin-1-yl]-(2,5-substituert-fenyl)metanonderivater som glycintransportor 1(GLYT-1)- inhibitorer for behandling av neurologiske og neuropsykiatriske lidelser
ATE545413T1 (de) Antagonisten des opioidrezeptors
BR0213393A (pt) Derivados de éter alquìlico e de alquilamida ou seus sais, processos para produzir um derivado de éter alquìlico, e, composição farmacêutica
BRPI0409110A (pt) derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer
PE20080068A1 (es) Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
AR040278A1 (es) Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos
BRPI0607600A2 (pt) derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina
UA100232C2 (uk) Кристалічні форми інгібітора glyt1
DE60111464D1 (de) Azabicycloalkan-Derivate zur Verwendung als Inhibitoren der Serotonin-Wiederaufnahme und als 5HT2a Antagonisten
PE20040911A1 (es) Derivados de 3h-quinazolin-4-ona como inhibidores selectivos de la monoaminooxidasa b
JP4762250B2 (ja) フェニル−ピペラジンメタノン誘導体
ATE475640T1 (de) Antagonisten des opioidrezeptors
BR0317422A (pt) Compostos de n-(indoletil) cicloamina
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
WO2007054444A3 (en) 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
RU2008148165A (ru) Замещенные производные фенилметанона
EP1473295A4 (en) CONDENSED BICYCLIC PYRIMIDINE DERIVATIVES
Barbay et al. Synthesis and characterization of 5, 6, 7, 8-tetrahydroquinoline C5a receptor antagonists
BRPI0414460A (pt) compostos derivados de carboxamida do tipo de amida, composição farmacêutica e respectivo uso

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.